
Opinion|Videos|March 20, 2025
Academic Perspectives on Systemic Therapy for Advanced uHCC
Author(s)Amit Mahipal, MD
An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy through imaging, α-fetoprotein levels, and tolerability. Treatment decisions are guided by response assessment, adverse events, and liver function. First-line (1L) options include tyrosine kinase inhibitors and immunotherapy combinations, with promising trials exploring novel immune combinations and targeted approaches that may reshape the treatment landscape.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What remaining clinical pearls can you share regarding systemic therapy treatment approaches for patients with advanced uHCC?
- How do you evaluate treatment success over time, and what are key indicators that guide decisions regarding treatment modifications or sequencing?
- What trials are you anticipating that might affect the 1L treatment of uHCC?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
3
Dostarlimab Demonstrates Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
4
What Long-Term Real-World Data on CAR T in Myeloma Could Reveal
5































